Integra LifeSciences IART Wound Reconstruction — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's wound reconstruction — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integra LifeSciences's wound reconstruction — total revenues?
- Integra LifeSciences (IART) reported wound reconstruction — total revenues of $79.65M in Q1 2026.
- How has Integra LifeSciences's wound reconstruction — total revenues changed year-over-year?
- Integra LifeSciences's wound reconstruction — total revenues increased by 6.5% year-over-year, from $74.78M to $79.65M.
- What is the long-term trend for Integra LifeSciences's wound reconstruction — total revenues?
- Over 4 years (2021 to 2025), Integra LifeSciences's wound reconstruction — total revenues has grown at a -4.7% compound annual growth rate (CAGR), from $392.46M to $323.49M.
- What does wound reconstruction — total revenues mean?
- This metric represents the total revenue generated from the sale of regenerative skin and wound care products, including advanced wound dressings and tissue-engineered solutions. It serves as a key indicator of the company's market penetration and demand within the regenerative medicine and surgical wound management sectors. Tracking this revenue stream helps investors assess the growth trajectory and competitive positioning of the company's specialized tissue technology portfolio.